Recent Updates
Recently added Catalysts
AGIO

Agios to Present at Morgan Stanley Global Healthcare Conference Tuesday, September 13, 2016

Key Takeaway: CAMBRIDGE, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the Morgan Stanley Global Healthcare Confe

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+80%
120-day peak, hindsight
Typical move
5%
average across 13 past catalysts
Cash runway
~50 mo
Minimal dilution risk
Lead asset
Mitapivat
Phase 3 · Transfusion-dependent Alpha-Thalassemia

Full Press Release Details

CAMBRIDGE, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 13, 2016 at 2:05 p.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
About Agios Pharmaceuticals
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Last updated: Sep 6, 2016